Please check your internet connection and try again.
# Hepa-Merz (L-Ornithine L-Aspartate / LOLA)
## Overview
Hepa-Merz is a stable salt of two endogenous amino acids, L-ornithine and L-aspartate. It acts by stimulating the urea cycle in the liver and promoting glutamine synthesis in the muscle, facilitating the detoxification of ammonia in patients with hepatic encephalopathy.
## Primary Indications
* Treatment of latent and manifest hepatic encephalopathy (HE).
* Adjunctive therapy for hyperammonemia associated with acute or chronic liver diseases (e.g., cirrhosis, fatty liver, hepatitis).
## Adult Dosing
* **Oral (Granules):** 3g to 6g three times daily, dissolved in liquid, taken after meals.
* **Intravenous (Ampoules):** 10g to 20g (up to 4 ampoules) per 24 hours in severe cases. Administer via slow infusion diluted in 500mL of IV fluid (e.g., normal saline or 5% glucose).
* **Maximum Rate:** Do not exceed 5g per hour to prevent nausea and vomiting.
## Pediatric Dosing
* **Safety/Efficacy:** Evidence is limited. Pediatric dosing is not standardized and generally not recommended. Use only under specialist guidance if risk-benefit analysis favors treatment.
## Dose Adjustments
* **Renal Impairment:** Reduce dosage or use with extreme caution in patients with severe renal impairment (serum creatinine > 3mg/100mL), as the kidneys are the primary route of excretion for the metabolic byproducts.
* **Hepatic Impairment:** No specific reduction required, but infuse slowly in patients with ascites or severe decompensation.
## Contraindications
* Hypersensitivity to the active ingredients.
* Severe renal failure (renal insufficiency as defined above).
## Adverse Effects
* **Common:** Nausea, vomiting, abdominal pain, diarrhea.
* **Rare:** Limb pain, allergic skin reactions, or injection site irritation.
## Key Drug Interactions
* **None Well-Established:** Generally safe to co-administer with lactulose or antibiotics used in HE (e.g., rifaximin). However, monitor for additive electrolyte imbalances if infused in large volumes.
## Monitoring
* **Clinical:** Monitor mental status, orientation, and severity of hepatic encephalopathy (e.g., West Haven criteria).
* **Laboratory:** Ammonia levels (though clinical signs are a better proxy), serum electrolytes, and renal function (BUN/Creatinine).
## Clinical Pearls
* **Administration:** IV infusions must be administered slowly. Rapid infusion is strongly linked to gastrointestinal distress.
* **Mechanism:** LOLA does not replace the need for identifying and treating precipitating factors of HE (e.g., GI bleeding, infection, electrolyte disturbances, or constipation).
* **Formulation:** Granules may contain carbohydrates; check labels for diabetic patients.
***
**Educational Disclaimer:** This information is for educational purposes only. Always consult your local formulary, hospital guidelines, and the manufacturer’s most recent Summary of Product Characteristics (SmPC) before prescribing or administering medication. Consult a healthcare professional for clinical decision-making.
